James C. Momtazee, Director at BridgeBio Pharma, Inc. (BBIO), bought 80,000 shares at $14.50 ($1.2M) on 2021-12-29, disclosed to the SEC on 2022-01-03.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.